Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan S Zager

Showing results (231-240 of 247) with videos related to

Pageof 25
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|July 5, 2014
Occult primary, version 3.2014David S Ettinger, Charles R Handorf, Mark Agulnik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2015
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced MelanomaRobert H I Andtbacka, Howard L Kaufman, Frances Collichio, et al.
Annals of Surgery|June 13, 2019
Preoperative Ultrasound Assessment of Regional Lymph Nodes in Melanoma Patients Does not Provide Reliable Nodal Staging: Results From a Large Multicenter TrialJohn F Thompson, Lauren E Haydu, Roger F Uren, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2026
Translating ctDNA into cutaneous melanoma care: An international expert surveyGlenn Geidel, Nathan Fekade, Katharina Raabe, et al.
European Journal of Cancer (Oxford, England : 1990)|January 26, 2024
Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapySarah K Jacques, Janet McKeown, Piyush Grover, et al.
Cancer|November 10, 2024
A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first-line treatment for patients with melanoma in-transit metastasesDanielle K DePalo, Michelle M Dugan, Syeda Mahrukh Hussnain Naqvi, et al.
Transplantation and Cellular Therapy|December 20, 2025
Safety and efficacy of tumor-infiltrating lymphocyte (TIL) therapy with reduced-dose lymphodepleting conditioning in high-risk metastatic melanoma patientsLilit Karapetyan, Joel Kuriakose, Elizabeth DiMaggio, et al.
Cancer Discovery|July 26, 2024
Preexisting Skin-Resident CD8 and γδ T-cell Circuits Mediate Immune Response in Merkel Cell Carcinoma and Predict Immunotherapy EfficacyZachary Z Reinstein, Yue Zhang, Oscar E Ospina, et al.
Journal of the American College of Surgeons|December 14, 2020
Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched AnalysisKristy K Broman, Tasha M Hughes, Lesly A Dossett, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 2022
The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases - A multicenter cohort studyCarl-Jacob Holmberg, Lars Ny, Tina J Hieken, et al.
Pageof 25

Showing results (231-240 of 247) with videos related to

Sort By:
Pageof 25
Journal of the National Comprehensive Cancer Network : JNCCN|July 5, 2014
Occult primary, version 3.2014David S Ettinger, Charles R Handorf, Mark Agulnik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2015
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced MelanomaRobert H I Andtbacka, Howard L Kaufman, Frances Collichio, et al.
Annals of Surgery|June 13, 2019
Preoperative Ultrasound Assessment of Regional Lymph Nodes in Melanoma Patients Does not Provide Reliable Nodal Staging: Results From a Large Multicenter TrialJohn F Thompson, Lauren E Haydu, Roger F Uren, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2026
Translating ctDNA into cutaneous melanoma care: An international expert surveyGlenn Geidel, Nathan Fekade, Katharina Raabe, et al.
European Journal of Cancer (Oxford, England : 1990)|January 26, 2024
Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapySarah K Jacques, Janet McKeown, Piyush Grover, et al.
Cancer|November 10, 2024
A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first-line treatment for patients with melanoma in-transit metastasesDanielle K DePalo, Michelle M Dugan, Syeda Mahrukh Hussnain Naqvi, et al.
Transplantation and Cellular Therapy|December 20, 2025
Safety and efficacy of tumor-infiltrating lymphocyte (TIL) therapy with reduced-dose lymphodepleting conditioning in high-risk metastatic melanoma patientsLilit Karapetyan, Joel Kuriakose, Elizabeth DiMaggio, et al.
Cancer Discovery|July 26, 2024
Preexisting Skin-Resident CD8 and γδ T-cell Circuits Mediate Immune Response in Merkel Cell Carcinoma and Predict Immunotherapy EfficacyZachary Z Reinstein, Yue Zhang, Oscar E Ospina, et al.
Journal of the American College of Surgeons|December 14, 2020
Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched AnalysisKristy K Broman, Tasha M Hughes, Lesly A Dossett, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 2022
The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases - A multicenter cohort studyCarl-Jacob Holmberg, Lars Ny, Tina J Hieken, et al.
Pageof 25